AN2 Therapeutics, Inc.ANTXNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
118.75%
↑ 627% above average
Average (18q)
16.34%
Historical baseline
Range
High:148.64%
Low:-58.39%
Volatility
1267.1%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 118.75% |
| Q2 2025 | -58.39% |
| Q1 2025 | 42.49% |
| Q4 2024 | -34.87% |
| Q3 2024 | -31.79% |
| Q2 2024 | -17.10% |
| Q1 2024 | -1.77% |
| Q4 2023 | 3.40% |
| Q3 2023 | 6.58% |
| Q2 2023 | 12.96% |
| Q1 2023 | 36.94% |
| Q4 2022 | 3.84% |
| Q3 2022 | 25.83% |
| Q2 2022 | 18.91% |
| Q1 2022 | -3.08% |
| Q4 2021 | 8.74% |
| Q3 2021 | 30.37% |
| Q2 2021 | 148.64% |
| Q1 2021 | 0.00% |